You just read:

Amgen Announces New Analyses Of High-Risk Patient Subgroups From Repatha® (evolocumab) Cardiovascular Outcomes Study At AHA Scientific Sessions 2017

News provided by

Amgen

Nov 06, 2017, 08:00 ET